Patient-specific ablation simulation
Confirm tumor coverage before every ablation.
Hapchot generates a patient-specific simulation of your ablation zone. Confirm coverage. Check margins. Then trigger.
The challenge
Percutaneous tumor ablation
is performed blind.
No real-time visualization of the treated zone. No patient-specific modeling. Practitioners rely on theoretical ablation zones that do not account for individual anatomy or tissue properties.
Up to 50%[2]
local recurrence rate
in some indications, leading to re-ablation and therapeutic escalation
* For irreversible electroporation (IRE) of hepatocellular carcinoma (HCC) tumors
Introducing Hapchot
Predictive dosimetry for interventional oncology
Peri-operative assistance for percutaneous tumor ablations
Thermal (Radiofrequency, microwave) and electroporation (IRE and ECT)
Patient-specific simulation of the ablation zone to confirm tumor coverage and correct needle placement before triggering treatment.
Treat with certainty — confirm coverage and correct needle position before triggering treatment.
Fewer local recurrences, fewer rehospitalizations — and the costs that come with them.
Precise treatment from the first procedure, limiting the risk of therapeutic escalation.
Clinical workflow
A frictionless peri-operative workflow. Any device. Any indication.
Hardware-agnostic and compatible with your existing imaging and ablation systems. Will be available for multiple solid tumor indications including liver, pancreas, prostate, and lung.
Phase 1
Planning
Plan the optimal needle strategy
Load patient CT or MRI imaging, segment the tumor, and run a predictive simulation to define the ideal needle placement.
Phase 2
Intra-operative guidance — after needles/applicators are placed
Elastic image fusion
Generate a new digital twin by fusing pre-op imaging with current intra-operative anatomy to confirm tumor location after positioning.
Verify coverage & treat
Simulate the ablation zone, confirm tumor coverage exceeds the safety threshold, and correct needle positions (if needed) before triggering treatment.
Competitive advantage
Every other tool shows you a generic ablation zone. Hapchot simulates the actual one.
Planning software provides theoretical ablation zones that don't account for actual anatomy. Hapchot closes that gap with patient-specific simulation, before treatment begins.
Status quo
No assistance
- No 3D visualization of coverage or margins
- No pre-operative planning tool
- Treatment triggered without coverage confirmation
High risk of recurrence[1,2]
Highly dependent on operator
Existing solutions
Planning software
- Generic zone estimates based on device manufacturer specs
- Rigid image registration — does not account for intra-operative deformation
- No patient-specific tissue modeling
Theoretical coverage ≠ actual coverage
Recurrence risk remains
Predictive dosimetry
Hapchot
- Elastic image registration — compensates for anatomical movements
- Predicted ablation zone based on actual anatomy and tissue properties
- Coverage and margins confirmed before treatment
Accurate coverage and margins assessment.
The conditions for local tumour control.
Clinical evidence
Why tumor coverage and margins are everything
Tumor coverage and adequate margins are the main technical goals of every ablation and the strongest predictors of local tumour control.
€6–15k[3]
cost per local recurrence
Per patient, in re-ablation, therapeutic escalation, and re-hospitalization costs.
Published evidence
31
patients
Retrospective clinical study — European Radiology, 2025
Sutter O., et al. “Towards Perioperative, Numerically-Assisted Irreversible Electroporation for Hepatocellular Carcinoma: Clinical Outcomes Informed by Numerical Simulations.”
Development roadmap
From clinical evidence
to standard of care
The path from research to regulatory approval in interventional oncology is measured in years. We're on it — and the institutions partnering with us today are shaping the clinical evidence that will define tomorrow's standard of care.
Research v1 — Electroporation dosimetry
Numerically-assisted electroporation for hepatic tumors. Retrospective study published in European Radiology (2025).
Research partnerships are currently open.
Research v2 — Thermal dosimetry
Full predictive simulation for radiofrequency (RFA) and microwave (MWA) ablation. Expands to liver, kidney, and pancreas indications.
v1 Commercial launch
CE marking (EU) for IRE dosimetry + thermal theoretical ablation zones. Commercial availability to interventional radiology departments.
v2 Commercial + Urology
Commercial launch of thermal dosimetry (CE mark early 2030). Hapchot for Urology — prostate cancer indication — commercially available 2031.
Developed in collaboration with AP-HP, INRIA, CNRS, and Université Sorbonne Paris Nord and more
Founding team
Product development, science, clinical, and business expertise
Pr. Olivier Seror, MD
Medical advisor
Head of Interventional Radiology @ Hôpital Avicenne, APHP
Hapchot co-creator
Dr. Olivier Sutter, MD
Medical advisor
Interventional Radiologist @ Hôpital Avicenne, APHP
Hapchot co-creator
Pr. Olivier Seror, MD
Medical advisor
Head of Interventional Radiology @ Hôpital Avicenne, APHP
Hapchot co-creator
Dr. Olivier Sutter, MD
Medical advisor
Interventional Radiologist @ Hôpital Avicenne, APHP
Hapchot co-creator
Research program
Partner with us
We're currently selecting research partner institutions for our clinical validation program. Early partners contribute to the evidence base and receive priority access at commercial launch.
References
- [1]Sutter O., et al. "Towards Perioperative, Numerically-Assisted Irreversible Electroporation for Hepatocellular Carcinoma: Clinical Outcomes Informed by Numerical Simulations" (2025).DOI: 10.1007/s00330-025-12223-7
Presented at World Congress of Electroporation 2024, Rome — and Journées Françaises de Radiologie 2024, Paris.
- [2]Stättner S., et al. "Ablative margins in percutaneous thermal ablation of hepatic tumors: a systematic review." Expert Review of Anticancer Therapy, 2023.
- [3]Charalel R., et al. "Short-Term Out-of-Pocket and Total Costs of Care After Ablation, Resection, or Transplant for Early-Stage Hepatocellular Carcinoma: A National SEER-Medicare Cost Comparison." AJR, vol. 223, 2024.
- [4]Paolucci I., et al. "International multisociety Delphi consensus for liver tumour thermal ablation: margin assessment." Lancet Oncology, 2026.
Endorsed by ESSE, CIRSE, and SIO. 72-expert Delphi consensus across North America, South America, Europe, and Asia.
- [5]Laimer G., et al. "International multisociety Delphi consensus for liver tumour thermal ablation: procedural and practice standards." Lancet Oncology, 2026.